<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-86039</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Repeated Daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction</dc:title>
<dc:description xml:lang="en">Daclizumab is an interleukin-2 receptor antagonist which is used for induction therapy in heart transplant patients. It has few side effects and is associated with a low infection rate. Postoperative renal failure after heart transplantation is common and potentially fatal. The administration of calcineurin inhibitors in the postoperative period can aggravate the situation. We report the cases of six patients who underwent heart transplantation and developed acute renal failure in the immediate postoperative period. All were administered daclizumab weekly to avoid the introduction of calcineurin inhibitors and to facilitate recovery of renal function. Calcineurin inhibitors were introduced only once renal function had improved. Renal function recovered in all cases and there was a low complication rate. The administration of repeated doses of daclizumab to patients who experience acute postoperative renal failure after heart transplantation may provide an alternative therapeutic approach that enables calcineurin inhibitors to be avoided and, consequently, renal function to recover(AU)</dc:description>
<dc:creator>Martínez Dolz, Luis</dc:creator>
<dc:creator>Buendía Fuentes, Francisco</dc:creator>
<dc:creator>Vicente Sánchez, José Luis</dc:creator>
<dc:creator>Agüero Ramón-Llin, Jaime</dc:creator>
<dc:creator>Salvador Sanz, Antonio</dc:creator>
<dc:creator>Almenar Bonet, Luis</dc:creator>
<dc:creator>Sánchez Lázaro, IGnacio J</dc:creator>
<dc:creator>Navarro Manchón, Josep</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El daclizumab es un antagonista del receptor de la IL-2 usado como terapia de inducción en el trasplante cardiaco con pocos efectos secundarios y baja tasa de infecciones. La insuficiencia renal postoperatoria tras un trasplante cardiaco es frecuente y potencialmente grave. La introducción de los inhibidores de la calcineurina en el postoperatorio puede agravar esta situación. Presentamos 6 casos de pacientes sometidos a trasplante cardiaco y que desarrollaron insuficiencia renal postoperatoria. En todos ellos se administró daclizumab de forma semanal para evitar la introducción del inhibidor de la calcineurina y permitir la recuperación renal. Una vez mejorada la función renal, se introdujo el inhibidor de la calcineurina. En todos los casos se recuperó la función renal y la tasa de complicaciones fue baja. La administración de dosis repetidas de daclizumab en pacientes con insuficiencia renal tras un trasplante cardiaco puede ser una alternativa para evitar el uso de inhibidores de la calcineurina y permitir así la recuperación de la función renal(AU)</dc:description>
<dc:source>Rev Esp Cardiol;64(3): 237-239, mar. 2011. tab</dc:source>
<dc:identifier>ibc-86039</dc:identifier>
<dc:title xml:lang="es">Dosis repetidas de daclizumab para retrasar la instauración del inhibidor de la calcineurina en pacientes con trasplante cardiaco y disfunción renal postoperatoria</dc:title>
<dc:subject>^d2346^s22031</dc:subject>
<dc:subject>^d2346^s22021</dc:subject>
<dc:subject>^d23811^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23811^s22000</dc:subject>
<dc:subject>^d3605^s22052</dc:subject>
<dc:subject>^d3605^s22021</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29419^s22045</dc:subject>
<dc:subject>^d11622^s22032</dc:subject>
<dc:subject>^d11443^s22012</dc:subject>
<dc:subject>^d33429^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201103</dc:date>
</metadata>
</record>
</ibecs-document>
